Timber Pharmaceuticals to Present at the Virtual Summer Summit 

Rhea-AI Summary

Timber Pharmaceuticals, focused on orphan dermatologic diseases, announces a presentation by CEO John Koconis at the Virtual Summer Summit on June 9, 2020, at 2:10 PM ET. The event, attracting over 500 executives and investors, will feature insights into Timber's development pipeline and upcoming milestones. Attendees can access the presentation via a provided link. Timber specializes in non-systemic treatments for rare conditions such as congenital ichthyosis and localized scleroderma, ensuring a strong focus on therapies with proven safety profiles.

Presentation on Tuesday, June 9^th at 2:10pm ET

WOODCLIFF LAKE, NJ, June 03, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases, today announced that John Koconis, CEO of Timber, will present a corporate overview of the company, its development pipeline and near-term milestones at the Virtual Summer Summit on Tuesday, June 9^th, 2020 at 2:10pm ET.

The Virtual Summer Summit will take place entirely online and feature over 500 registered executives and qualified investors viewing virtual company presentations and attending one-on-one meetings. 

To attend the virtual presentation, please go to the following link on Tuesday, June 9th at 2:10pm ET: https://www.webcaster4.com/Webcast/Page/2038/35017

For more information, please visit: www.microcapconf.com.

About Timber Pharmaceuticals, Inc.

Timber Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for orphan dermatologic diseases. The company's investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing, and control) and safety profiles. Timber is initially focused on developing non-systemic treatments for rare dermatologic diseases including congenital ichthyosis (CI), facial angiofibromas in tuberous sclerosis complex (TSC), and localized scleroderma. For more information, visit www.timberpharma.com.

For more information, contact:

Timber Pharmaceuticals, Inc. 
John Koconis 
Chief Executive Officer
jkoconis@timberpharma.com

Investor Relations:
Stephanie Prince
PCG Advisory
(646) 762-4518
sprince@pcgadvisory.com

Media Relations: 
Adam Daley
Berry & Company Public Relations 
212-253-8881
adaley@berrypr.com

FAQ

What is Timber Pharmaceuticals' focus for its treatments?

Timber Pharmaceuticals focuses on developing treatments for orphan dermatologic diseases.

When will Timber Pharmaceuticals present at the Virtual Summer Summit?

Timber Pharmaceuticals will present on June 9, 2020, at 2:10 PM ET.

Who is the CEO presenting for Timber Pharmaceuticals?

John Koconis is the CEO presenting for Timber Pharmaceuticals.

How can I attend the Timber Pharmaceuticals presentation?

You can attend the presentation by visiting the provided link on June 9, 2020, at 2:10 PM ET.

What rare diseases is Timber Pharmaceuticals targeting?

Timber Pharmaceuticals is targeting congenital ichthyosis, facial angiofibromas in tuberous sclerosis complex, and localized scleroderma.